A Combination Strategy of Ceftriaxone, Sulbactam and Disodium Edetate for the Treatment of Multi-Drug Resistant (MDR) Septicaemia: A Retrospective, Observational Study in Indian Tertiary Care Hospital
Published: November 1, 2015 | DOI: https://doi.org/10.7860/JCDR/2015/.6840
Umakant Nagashetty Patil, Kiran Lakkol Jambulingappa
1. Professor and Head, Department of Pharmacology, SS Institute of Medical Sciences and Research Centre, NH4 Bypass Road, Davangere, Karnataka, India.
2. Associate Professor, Department of Pharmacology, SS Institute of Medical Sciences and Research Centre, NH4 Bypass Road, Davangere, Karnataka, India.
Correspondence
Dr. Umakant Nagashetty Patil,
Professor and Head, Department of Pharmacology, SS Institute of Medical Sciences and Research Centre,
NH4 Bypass Road, DAVANGERE, Karnataka-577005, India.
E-mail : drunpatil@gmail.com
Introduction: Previous studies have suggested the use of rational combination therapy for the treatment of multi-drug resistant (MDR) infections. An antibiotic adjuvant entity (AAE) of ceftriaxone, sulbactam and disodium edetate (Elores) was approved for multi-drug resistant infections in India.
Aim: This study was designed to investigate the efficacy and safety of this AAE in patients with sepsis due to extended spectrum beta lactamse (ESBL) and metallo-beta lactamase (MBL) producing pathogens.
Materials and Methods: A retrospective observational study was conducted in patients admitted in intensive care unit (ICU) at tertiary health care site in India, with enrollment from 24 March, 2012 to 7 Aug, 2012. Patients eligible for enrollment had clear infection of bacterial septicaemia, were aged 12-65 years, and were considered for treatment with Cephalosporins categories of antibiotics.
Results: Total 18 patients were included in the study and all assigned to combination of ceftriaxone, sulbactam and disodium edetate. Complete clinical cure in terms of relief and no-disease symptoms had observed in 15 (83.3%) subjects, however 3 (16.6%) showed treatment failure (TF). Similarly for bacteriological eradication response, 15 (83.3%) patients displayed complete bacteriological eradication response and 03 (16.6%) subjects showed TF. No serious side effect was observed during the study.
Conclusion: This study recommends the use of combination of ceftriaxone, sulbactam and disodium edetate (EDTA) for the treatment of MDR septicaemia associated with ESBL and MBL producing microbes.
[
FULL TEXT ] | [ PDF]